By Kathryn Hardison
Shares of Imara Inc. fell 11% to $3.39 Monday after the company's all-stock deal to merge with oncology company Enliven Therapeutics Inc. sent shares higher Friday.
The combined company, which will be called Enliven Therapeutics Inc., will focus on Enliven's pipeline of precision oncology product candidates, the companies said late Thursday. The combined company will trade on the Nasdaq Global Select Market under the ticker symbol ELVN.
Shareholders of both companies still need to approve the merger, though Imara and Enliven said they expect the deal to close in the first quarter of next year.
Shares on Friday reached an intraday high of $3.82 before closing at $3.79, according to FactSet.
Shares Monday traded 51% higher for the year.
Write to Kathryn Hardison at kathryn.hardison@wsj.com
(END) Dow Jones Newswires
October 17, 2022 12:11 ET (16:11 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。